Dr. Wurtman has served as President & CEO of Lyric Pharmaceuticals, an ICU therapeutic development company which he founded, and as CMO of Lucid Diagnostics, a medical device-diagnostic company which he helped take public in 2021. He has led or advised on ~30 licensing deals and M&A transactions and raised over $70MM from Venture Capital, Private Equity, Family Office and US Government. He has deep development expertise across drugs, biologics, and diagnostic devices and has led successful FDA interactions, including obtaining FDA Breakthrough Designation. Dr. Wurtman has previously held roles in Corporate, Business and Product Development at Genzyme, Protein Design Labs, Eos Biotechnology, Kineta and Ansun Biopharma. He has consulted to more than 25 biopharmaceutical, technology platform, medical device, diagnostic, and healthcare IT companies on corporate strategy, fundraising, mergers & acquisitions, business development & licensing, product development, market research, product positioning, and clinical-regulatory strategy and development. Dr. Wurtman received his AB from Harvard College, MD from Harvard Medical School, and MBA from the MIT Sloan School of Management. He completed a primary care internal medicine residency at Mt. Auburn Hospital, a Harvard teaching hospital, and practiced Primary Care at Harvard Community Health Plan as a board-certified physician in Internal Medicine.